Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience.

This article focuses on evaluating patient preference, satisfaction, and effectiveness of subcutaneous immunoglobulin (SCIG) therapy compared to intravenous immunoglobulin (IVIG) in patients with idiopathic inflammatory myopathies (IIMs), a group of diseases characterized by skeletal muscle inflammation and systemic involvement. In a retrospective study of 20 IIM patients transitioned from IVIG to SCIG for over 12 months, most patients (78.9%) preferred SCIG, favoring home-based administration without significant changes in disease activity measured by the Myositis Intention to Treat Index (MITAX) or cumulative corticosteroid use. The study found SCIG to be a safe and effective maintenance therapy with minimal adverse effects, suggesting potential benefits in patient autonomy and healthcare resource utilization. Future prospective and cost-effectiveness studies are recommended to further define SCIG’s role in IIM management.